Secondary myelodysplastic syndromes following peripheral blood stem cell transplantation: morphological, cytogenetic and clonality evaluation and the limitation of FAB criteria
We read with interest the article of Amigo et al 1 dealing with the diagnosis of secondary myelodysplastic syndrome (MDS) following autologous transplantation. The authors believe that the application of FAB criteria for diagnosis of MDS after autologous transplant is questionable since the concomitant presence of cytopenia and myelodysplasia was observed in 25% of patients at 12 months and they could therefore, diagnose MDS according to FAB classification. On the basis of our experience we can confirm these statements.
Since 1996 we studied 52 patients (21 F; 31 M) submitted to peripheral blood selected (CD34 + ) (16 patients) or unselected autologous stem cell transplantation (36 patients). Reasons for transplantation were non-Hodgkin's lymphoma (26 patients), Hodgkin's lymphoma (13 patients) and multiple myeloma (13 patients). The purpose of the study was to detect MDS/sAML after transplantation and any morphological dysplasia, cytogenetic or clonality alterations. 2, 3 All patients entering the study had had at least 12 months follow-up and had to be in continuous complete remission after PBPCT without receiving any chemoradiotherapy or biological response modifier.
We performed annual follow-up visits including bone marrow smear to detect dysplastic features in erythroid, granulocytic and megakaryocytic lineages and cytogenetic analysis. Clonality analysis was studied by an X-inactivation based clonality assay at the human androgen receptor locus (HUMARA) in female patients. Whenever evidence of dysplastic change and/or cytogenetic and clonality alteration was detected, patients were contacted for strict monitoring. Dyserythropoietic features were defined according to Brito-Babapulle et al 4 as more than 25% dysplastic features in at least 100 erythroblasts, dysgranulopoiesis as more than 50% of dysplastic features in at least 100 myelocytes, metamyelocytes or neutrophils and dysmegakaryocytic features as more than 50% of dysplastic changes in at least five megakaryocytes in order to predict possible future MDS/sAML evolution. 5 Each patient was evaluated on one to four occasions (Table 1) for a total of 115. The median follow-up after transplantation was 24 months (range 12-97 months) ( Table 1) . Only two patients (UPN 125, 153) showed dyserythropoiesis on bone marrow examination before transplantation without cytogenetic abnormalities in both patients or clonality alteration in the female patient. Both patients are alive with a follow-up of 12 and 25 months, respectively, with persistent unilineage dysplasia but not sufficient for a FAB diagnosis of MDS/RA. Seven patients (UPN 26, (Table 2 ). In our opinion dysplastic changes and in particular cytogenetic and clonality alterations are useful as parameters predicting future myelodysplasia, but each of them alone is not sufficient to allow a diagnosis of myelodysplastic syndrome according to the FAB classification in the post-transplant period. The first evaluation of MDS post PBPCT should be done after 1 year allowing bone marrow reconstitution and cellularity without any effect induced by the conditioning regimen. In the article of Amigo et al, the hypocellularity was more evident after 6 months than after 1 year and the dysplastic criteria adopted were too inflexible to be reproducible at the next morphological follow-up and have prognostic significance. We excluded from our study acute and chronic leukemia because of the blast contamination and myelodysplastic change often present at diagnosis. 6 Dysplastic changes, cytogenetic and clonal alterations should be detected to predict the development of MDS/sAML after PBPCT. FAB criteria are not easily applicable especially in the case of refractory anemia (RA) because the degree of cytopenia and lineage dysplasia necessary to consider a patient as having secondary MDS/RA is not specified. 
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